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Abstract: Aging, multimorbidity, and polypharmacy are associated with medication-related problems
(MRPs). This study aimed to assess the association that multimorbidity and mortality have with
MRPs in older people over time. We followed multimorbid, older (65–99 years) people in Catalonia
from 2012 to 2016, using longitudinal data and Cox models to estimate adjusted hazard ratios (HR).
We reviewed electronic health records to collect explanatory variables and MRPs (duplicate therapy,
drug–drug interactions, potentially inappropriate medications (PIM), and contraindicated drugs in
chronic kidney disease (CKD) or liver disease). There were 723,016 people (median age: 74 years;
58.9% women) who completed follow-up. We observed a significant (p < 0.001) increase in the
proportion with at least one MRP (2012: 66.9% to 2016: 75.5%); contraindicated drugs in CKD (11.1 to
18.5%) and liver disease (3.9 to 5.3%); and PIMs (62.5 to 71.1%), especially drugs increasing fall risk
(67.5%). People with ≥10 diseases had more MRPs (in 2016: PIMs, 89.6%; contraindicated drugs in
CKD, 34.4%; and in liver disease, 9.3%). All MRPs were independently associated with mortality,
from duplicate therapy (HR 1.06; 95% confidence interval (CI) 1.04–1.08) to interactions (HR 1.60;
95% CI 1.54–1.66). Ensuring safe pharmacological treatment in elderly, multimorbid patient remains
a challenge for healthcare systems.
Keywords: multimorbidity; polypharmacy; drug interactions; duplicate therapy; contraindicated
drugs; inappropriate prescribing; primary health care; elderly
1. Introduction
More than a third of the population over the age of 50 years in Europe, and 39% in
Spain, presents multimorbidity, defined as having at least two chronic diseases [1]. Age is
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an important determinant of multimorbidity, with people’s risk increasing as they grow
older [2,3]. Another factor frequently associated with multimorbidity is polymedication
(routine use of five or more medications), which often arises from the application of
disease-centered clinical practice guidelines, resulting in patients receiving all the indicated
treatments for a single pathology, without regard to the other diseases that they may
have [4]. Furthermore, treatment indications are seldom adjusted by age group. This aspect,
together with the fragmentation of patient care at different healthcare levels, makes it
difficult to obtain a holistic understanding of which treatments should be recommended [5].
Medication-related problems (MRPs) are defined as any event or situation wherein
medicines may actually or potentially impede the achievement of positive health out-
comes [6]. Numerous studies have aimed to quantify MRPs in the hospital setting; however,
these problems are also prevalent in primary health care (PHC), where drug treatments
are among the most common resources deployed. Polymedication increases the risk of
MRPs [7]. As the promotion of patient safety has emerged as a priority for health systems
worldwide, in 2017 the World Health Organization (WHO) set a target to cut the global
level of severe, avoidable harms related to medications in half by 2022 [8].
The APEAS study, a cross-sectional observational study in 48 PHC centers in 16 semi-
autonomous regions of Spain, aimed to assess the frequency of adverse events and the fac-
tors contributing to their appearance, their severity, and their amenability to prevention [9].
The authors found that medications are a causal factor in 48% of patient safety incidents in
PHC, and of these, 58% are preventable. Advanced age, polymedication, and multimorbid-
ity are among the risk factors commonly related to MRPs [10], the most serious of which
may precipitate an emergency room visit, hospital admission, or death [11,12].
Older patients have certain characteristics that make them especially vulnerable to
MRPs. Multimorbidity, polymedication, and changes in drug pharmacodynamics and
pharmacokinetics affect most people over the age of 65 years [13,14]. Despite the increasing
prevalence of multimorbidity and its cascading impacts on MRPs, patients, and health
systems, we are not aware of any longitudinal studies that analyze MRP-related risks in
older people with multimorbidity. The aims of this study were to evaluate the relationship
between MRPs and multimorbidity in patients over 65 years of age and receiving treatment
in primary health care (PHC) in Catalonia (Spain) from 2012 to 2016 and to study five-year
mortality related to MRPs.
2. Materials and Methods
2.1. Design, Setting, and Study Population
This retrospective study with longitudinal data took place in Catalonia, a Mediter-
ranean region of Spain with 7,675,217 inhabitants in 2019 [15] and a decentralized, univer-
sal health coverage model financed by tax revenue and encompassed under the Spanish
National Health System. The Catalan Health Institute oversees 285 PHC centers, serv-
ing 5,501,784 patients (74% of the population); other providers manage the remaining PHC
centers [16].
We included people who: were aged 65 to 99 years on 31 December 2011, lived at least
until 31 December 2012 (index date), presented multimorbidity in 2012 or 2016, and made
at least one visit to PHC during the five-year study period (2012–2016). The cohort was
closed to new entries; attrition was the result of mortality or loss to follow-up due to
transfer to different health systems.
2.2. Dataset
The Catalan Health Institute’s Information System for Research in Primary Care
(SIDIAP) stores information from electronic health records (EHR), recorded in PHC centers
since 2006 [17]. The SIDIAP database contains anonymized EHRs from PHC and secondary
care, with longitudinal information on demographics, socioeconomic status, diagnoses,
symptoms, and prescriptions.
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The medication database covers all drugs that are dispensed, subsidized, and billed
by the national health service. To identify problems associated with the most relevant
medications, we included only drugs for systemic use, excluding medications with local
effects (e.g., topical drugs). This database does not cover medication administered in
hospitals or dispensed by hospital pharmacies, nor drugs that are not subsidized through
public healthcare services.
2.3. Variables
All variables were obtained directly from the SIDIAP database [18].
2.3.1. Chronic Diseases and Multimorbidity
The SIDIAP database codes diseases using the International Classification of Diseases,
10th revision (ICD-10). We considered multimorbidity as the presence of two or more
chronic diseases, defined using 60 selected groups of chronic diseases described in the
Swedish National Study of Aging and Care in Kungsholmen (SNAC-K) [19], which was
based on ICD-10 diagnostic codes, along with certain clinical, laboratory, and medication-
related parameters. Patients were classified into four multimorbidity categories according
to the number of pathologies they had: 0 to 1; 2 to 4; 5 to 9; and 10 or more chronic diseases.
The number of different chronic diseases per patient was collected at baseline (2012) and
study end (2016).
2.3.2. Drugs
We obtained data for drug exposure from the Pharmacy Invoice Registry. This registry
records drugs prescribed by PHC and hospital physicians. The drugs were categorized
according to the fourth and fifth levels of the Anatomical Therapeutic Chemical Classifi-
cation System (ATC) [20], facilitating analysis and interpretation. When the person used
three packages of the drug per year during the study period, this was considered chronic
use. Packages were defined as the pre-prepared packet of drugs constituting the sales
unit of medications available in the pharmacy; these frequently contain the number of
doses needed for one month of the indicated treatment. Drugs were coded as dichotomous
variables [21], and we classified patients into five categories according to the number of
different prescription drugs they were on: 0; 1; 2 to 4; 5 to 9; 10 or more.
2.3.3. Kidney Function
Impaired kidney function was defined by one of the two following parameters:
(a) Glomerular filtration rate (GFR): using the MDRD-4 IDMS equation, kidney function
was determined by estimating the GFR [22]. GFR values of less than 60 mL/min/1.73 m2
indicated impaired kidney function.
(b) ICD-10 codes for chronic kidney disease (CKD) were taken from SNAC-K criteria [23].
2.3.4. Liver Function
Impaired liver function was defined by one of the two following parameters:
(a) Abnormal liver function values: alkaline phosphatase (ALP) > 2 × 129 IU/L; alanine
transaminase (ALT) > 5 × 41 IU/L (men) or ALT > 5 × 33 IU/L (women); and gamma-
glutamyl transpeptidase (GGT) > 61 IU/L [24].
(b) ICD-10 codes for chronic liver disease were taken from SNAC-K criteria [23].
2.3.5. Other Variables
Additional variables collected at baseline and/or study end were sociodemographic
variables (age at baseline, gender, and socioeconomic status according to MEDEA index
quintiles from least to most deprived) [25] along with the number of total visits to PHC.
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2.3.6. Medication-Related Problems
We analyzed the following MRPs: duplicate therapy, drug–drug interactions, poten-
tially inappropriate medications (PIMs) in people aged 65 years or older, contraindicated
drugs in CKD, and contraindicated drugs in liver disease. Analysis of the MRPs began
by first building tables with medicines and combination drug treatments associated with
potential safety concerns:
- Duplicate therapy: prescription of two or more drugs that have the same pharma-
cological activity. We included duplicate therapies that posed an important clinical
risk, according to professional consensus. Our study did not consider combinations
of active principles with the same pharmacological action that physicians used to
achieve a synergistic effect or to adjust doses [23].
- Drug–drug interaction: when one drug’s activity or effect alters the action of another.
We focused on interactions that were life-threatening due to therapeutic failure or tox-
icity, identifying interactions with the highest level of severity (contraindication) from
the Thesaurus des interactions médicamenteuses from France’s Agence Nationale de Sécurité
du Médicament et des Produits de Santé (ANSM) [26] and comparing that information
with a second source [27,28] or contrasting it with professional consensus [23].
- Contraindicated drugs in CKD: we identified these drugs from the Catalan Health
Department’s consensus recommendation for patients with CKD [23,29].
- Contraindicated drugs in liver disease: the Spanish College of Pharmacists database
was used to identify these [23,30].
- PIMs in older people (≥65 years old): when the risk of adverse events associated
with the drug exceeded the expected clinical benefits, and there was no clear scientific
evidence pointing to a specific indication or supporting its cost-effectiveness. We pri-
marily used the STOPP/START criteria [31], which was complemented with Beers’
criteria [32], PRISCUS, and updates from other sources [33–40]. Different definitions of
PIMs exist: Durán et al. defined them as drug combinations with a clinically relevant
anticholinergic effect [38], while other authors have included drugs that increase the
risk of falling or affect the QT interval with known risk, antiulcer agents administered
without considering gastroprotection, and other drugs that are inadvisable for older
people or patients needing gastroprotection [23].
2.4. Ethics
The Clinical Research Ethics Committee of the Fundació Institut Universitari per a la
Recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol) (Protocol No: P17/080)
approved the study protocol. Data were fully anonymized, and the confidentiality of the
EHR was guaranteed at all times in accordance with national and international law.
2.5. Statistical Analysis
We used descriptive statistics to summarize the dataset, expressing categorical vari-
ables as absolute and relative frequencies and continuous variables as mean (standard
deviation, SD) or median (interquartile range, IQR), as appropriate. Differences between
multimorbidity groups that completed the follow-up at each study time point were as-
sessed using the chi-square test or the Mann–Whitney U test. The McNemar and Wilcoxon
tests were applied to compare prevalence of MRPs and use of PIMs between multimor-
bidity groups at baseline and at five years’ follow-up. The effect of age on the prevalence
of MRPs and the use of PIMs were also studied, using data from 2012. For this purpose,
two logistic regressions were performed for each MRP and PIM, one only with age and the
other by multimorbidity group at baseline, adjusting for age. Multinomial logistic regres-
sions were used to study the influence on the use of PIMs in terms of their anticholinergic
effect–anticholinergic load, in both cases.
To estimate mortality hazard for each MRP (duplicate therapy, drug–drug interactions,
contraindicated drugs in CKD, contraindicated drugs in liver disease, and PIMs), we fitted
Cox proportional-hazards regression models. Length of follow-up was the time elapsed
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from the index date to all-cause death. For the survival analysis, we followed patients
until loss to follow-up (censored) or end of observation. Hazard ratios (HRs) and 95%
confidence intervals (CIs) were adjusted for age, sex, socioeconomic status (MEDEA index),
and level of multimorbidity at baseline. The proportional hazard assumption was assessed
by means of the Schoenfeld residuals. We employed multiple imputation to minimize any
selection bias stemming from missing values for MEDEA (7%) and chained equations to
obtain seven imputed datasets. The multiple imputation datasets were incorporated into
the final models according to Rubin’s rules for combining effect estimates and standard
errors, which allowed for some uncertainty related to missing data.
Analyses were performed using SPSS for Windows (version 25, SPSS Inc., New York,
NY, USA), Stata 15 Stata/MP (version 15 for Windows, Stata Corp. LP, College Station,
TX, USA), and R (version 4.0.3, R Foundation for Statistical Computing, Vienna, Austria).
p values of less than 0.05 were considered significant.
3. Results
A total of 916,619 people aged 65 years or older were included in the database; 853,085
met the multimorbidity criteria, and 723,016 of these completed five years of follow-up,
as shown in Figure 1. This population’s median age was 74 years (IQR 68 to 79), and 58.9%
were women. At five years, there was an increase in the proportion of people taking 5 to
9 drugs (39.8% vs. 43.1%, p < 0.001) and more than 10 drugs (12.6% vs. 15.4%, p < 0.001).
Likewise, a higher percentage of patients presented altered liver or kidney function and
visited PHC 10 times or more per year, as shown in Table 1.
MRPs were highly prevalent in the study population and increased over time: 66.9%
of the patients had at least one MRP in 2012, compared to 75.5% in 2016, as shown in
Figure 2a. Changes in the type of MRP varied over the study period, with a drop in
duplicate therapies (11.3% vs. 6.2%) and drug–drug interactions (0.9% vs. 0.5%). In contrast,
the use of contraindicated medicines in CKD and liver disease as well as PIMs had risen by
study end, as shown in Figure 2b.
In all cases, patients’ MRPs increased with the number of chronic diseases; those with
10 or more had the highest prevalence of MRPs both at baseline and study end. At the
end of follow-up, 89.6% of this subgroup were taking PIMs; 34.4%, contraindicated drugs
with CKD; and 10.1%, duplicate therapy; smaller proportions had other MRPs, as shown
in Table 2. In addition, after adjusting for age, the association between MRPs and mul-
timorbidity was still significant, as shown in Table S1. The most common PIMs in the
whole study population at five-year follow-up were drugs increasing the risk of falling
(67.5%); this figure was higher in the subgroup with 10 or more comorbidities, as shown in
Table 3. In 2016, 48.4% of the study population was taking at least two PIMs, along with
8.3% who were taking at least two contraindicated drugs in CKD, and 2.9%, at least two
contraindicated drugs in liver disease, as shown in Table S2.
The most common contraindicated drugs in CKD were metformin (4.3%), hydroch
lorothiazide (both as monotherapy (2.8%) and in fixed-dose combination with enalapril
(2.1%)), and citalopram (1.6%), as shown in Table S3. In liver disease, the main contraindi-
cated drugs were simvastatin (1.9%), furosemide (1.2%), and metformin (1.0%), as shown
in Table S4. The most frequent PIMs were omeprazole, used without gastroprotective
criteria (23.3%); lorazepam, due to the increased risk of falling (14.8%); and bisoprolol,
in patients concomitantly taking anticholinesterase, due to the risk of cardiac conduction
failure, syncope, or heart damage (11.6%), as shown in Table S5.
People with MRPs were at higher risk of death—especially in the case of drug–drug
interactions (HR 1.62, 95% CI 1.55 to 1.70), followed by patients taking contraindicated
drugs in liver disease (HR 1.59, 95% CI 1.56 to 1.63) and those on PIMs (HR 1.31, 95% CI
1.29 to 1.32), as shown in Table 4.




Figure 1. Longitudinal flow chart of patients meeting initial inclusion criteria, without consideration for the multimorbidity criterion (2012–2016; N = 916,619 people).
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Variables  n (%) *  n (%) *  n (%) *  n (%) * 
Sex, women, n (%)    73,137 (53.1)  22,9870 (58.4)  123,014 (64.2)  426,021 (58.9) 
Age, median (IQR)  71.00 [67.00,76.00]  73.00 [68.00;79.00]  76.00 [71.00;80.00]  74.00 [68.00;79.00] 
Rural  30,094 (22.5)  78,760 (20.6)  31,752 (17.2)  140,606 (20.1) 
MEDEA Index †       
Figure 2. (a) Frequencies and (b) types of medication-related problems (MRPs) in older people with multimorbidity at baseline (2012) and at end of study (2016) (N = 723,016).
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n (%) * n (%) * n (%) * n (%) *
Sex, women, n (%) 73,137 (53.1) 229,870 (58.4) 123,014 (64.2) 426,021 (58.9)
Age, median (IQR) 71.00 [67.00,76.00] 73.00 [68.00;79.00] 76.00 [71.00;80.00] 74.00 [68.00;79.00]
Rural 30,094 (22.5) 78,760 (20.6) 31,752 (17.2) 140,606 (20.1)
MEDEA Index †
Q1 26,608 (19.9) 63,322 (16.6) 27,986 (15.1) 117,916 (16.8)
Q2 22,006 (16.5) 62,570 (16.4) 30,182 (16.3) 114,758 (16.4)
Q3 20,866 (15.6) 63,789 (16.7) 31,480 (17.0) 116,135 (16.6)
Q4 19,243 (14.4) 61,187 (16.0) 32,159 (17.4) 112,589 (16.1)
Q5 14,944 (11.2) 52,323 (13.7) 31,567 (17.1) 98,834 (14.1)
Number of drugs 2012 2016 2012 2016 2012 2016 2012 2016
0 34,937 (25.4) 26,903 (19.5) 32,578 (8.3) 16,833 (4.3) 7104 (3.7) 1918 (1.0) 74,619 (10.3) 45,654 (6.3)
1 21,226 (15.4) 21,234 (15.4) 24,267 (6.2) 19,235 (4.9) 2774 (1.5) 1661 (0.9) 48,267 (6.7) 42,130 (5.8)
2–4 57,435 (41.7) 62,554 (45.4) 136,887 (34.8) 130,158 (33.1) 26,751 (14.0) 19,860 (10.4) 221,073 (30.6) 212,572 (29.4)
5–9 22,892 (16.6) 25,954 (18.8) 169,574 (43.1) 191,213 (48.6) 95,389 (49.8) 94,522 (49.4) 287,855 (39.8) 311,689 (43.1)
≥10 1309 (1.0) 1154 (0.8) 30,366 (7.7) 36,233 (9.2) 59,527 (31.1) 73,584 (38.4) 91,202 (12.6) 110,971 (15.4)
Number of visits
0 13,639 (9.9) 10,299 (7.5) 12,374 (3.1) 5901 (1.5) 3147 (1.6) 858 (0.5) 29,160 (4.0) 17,058 (2.4)
1 11,341 (8.2) 10,419 (7.6) 10,723 (2.7) 9130 (2.3) 1523 (0.8) 1276 (0.7) 23,587 (3.3) 20,825 (2.9)
2–4 38,129 (27.7) 38,161 (27.7) 57,257 (14.5) 52,043 (13.2) 10,123 (5.3) 8725 (4.6) 105,509 (14.6) 98,929 (13.7)
5–9 45,344 (32.9) 46,684 (33.9) 128,738 (32.7) 123,262 (31.3) 37,760 (19.7) 32,163 (16.8) 211,842 (29.3) 202,109 (28.0)
≥10 29,346 (21.3) 32,236 (23.4) 184,580 (46.9) 203,336 (51.7) 138,992 (72.6) 148,523 (77.5) 352,918 (48.8) 384,095 (53.1)
CKD 6809 (4.9) 10,907 (7.9) 53,110 (13.5) 96,875 (24.6) 49,182 (25.7) 88,954 (46.4) 109,101 (15.1) 196,736 (27.2)
Chronic liver
disease 4495 (3.3) 5228 (3.8) 22,105 (5.6) 26,888 (6.8) 16,883 (8.8) 22,511 (11.8) 43,483 (6.0) 54,627 (7.6)
CKD: chronic kidney disease. Note: All variables of the table showed a significant difference (p < 0.001) between groups. * Unless otherwise noted. † MEDEA is a deprivation index measured in quintiles (Q),
from Q1 (least deprived) to Q5 (most deprived). Missing values n = 22,178. IQR: interquartile range.
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n (%) n (%) n (%) n (%)
2012 2016 2012 2016 2012 2016 2012 2016
Duplicate therapy 6853 (5.0) 3565 (2.6) 40,507 (10.3) 22,070 (5.6) 33,997 (17.8) 19,370 (10.1) 81,357 (11.3) 45,005 (6.2)
Drug–drug interactions 396 (0.3) 172 (0.1) 2616 (0.7) 1473 (0.4) 3100 (1.6) 1817 (1.0) 6112 (0.9) 3462 (0.5)
Contraindicated drugs in CKD 3606 (2.6) 5199 (3.8) 37,386 (9.5) 62,808 (16.0) 39,474 (20.6) 65,962 (34.4) 80,466 (11.1) 133,969 (18.5)
Contraindicated drugs in liver disease 2012 (1.5) 2495 (1.8) 13,812 (3.5) 17,959 (4.6) 12,302 (6.4) 17,790 (9.3) 28,126 (3.9) 38,244 (5.3)
Potentially inappropriate medication 49,999 (36.3) 60,353 (43.8) 245,447 (62.4) 282,150 (71.7) 156,710 (81.8) 171,641 (89.6) 452,156 (62.5) 514,144 (71.1)
CKD: chronic kidney disease. Note: All variables of the table showed a significant difference (p < 0.001) between groups.
Table 3. Potentially inappropriate medications in older people by multimorbidity group at baseline and at the end of the study (N = 514,144).
N Comorbidities









n (%) n (%) n (%) n (%)
2012 2016 2012 2016 2012 2016 2012 2016
Anticholinergic effect–anticholinergic load*
Score = 1 7011 (11.6) 10,910 (18.1) 42,699 (15.1) 61,400 (21.8) 34,069 (19.9) 45,155 (26.3) 83,779 (16.3) 117,465 (22.9)
Score = 2 3614 (6.0) 5104 (8.5) 25,833 (9.2) 32,771 (11.6) 22,269 (13.0) 27,232 (15.9) 51,716 (10.1) 65,107 (12.7)
Score = 3–5 1209 (2.0) 1499 (2.5) 9929 (3.5) 13,023 (4.6) 11,885 (6.9) 15,429 (9.0) 23,023 (4.5) 29,951 (5.8)
Score ≥ 6 39 (0.1) 37 (0.1) 307 (0.1) 315 (0.1) 484 (0.3) 436 (0.3) 830 (0.2) 788 (0.2)
Increase in fall risk 26,366 (43.7) 36,430 (60.4) 145,741 (51.7) 184,449 (65.4) 107,661 (62.7) 125,913 (73.4) 279,768 (54.4) 346,792 (67.5)
Effect on QT interval 4834 (8.0) 6814 (11.3) 34,387 (12.2) 43,157 (15.3) 32,334 (18.8) 37,491 (21.8) 71,555 (13.9) 87,462 (17.0)
Antiulcer agents without criteria for
gastroprotection 11,821 (19.6) 15,761 (26.1) 81,766 (29.0) 99,292 (35.2) 65,395 (38.1) 74,812 (43.6) 158,982 (30.9) 189,865 (36.9)
Other drugs not recommended for older people 9396 (15.6) 24,069 (39.9) 72,664 (25.8) 141,221 (50.1) 65,478 (38.2) 109,566 (63.8) 147,538 (28.7) 274,856 (53.5)
Patients needing gastroprotection 70 (0.1) 132 (0.2) 524 (0.2) 683 (0.2) 344 (0.2) 325 (0.2) 938 (0.2) 1140 (0.2)
Note: All variables of the table showed a significant difference (p < 0.001) between groups. * Score = 0 Not shown.
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Table 4. Mortality related to medication-related problems in older people with multimorbidity at baseline year (N = 853,085).
Medication-Related Problems HR (Crude)95% CI
Complete Case Analysis
HR (Adjusted) * 95% CI
Multiple Imputation
HR (Adjusted) * 95% CI
Duplicate therapy 1.14 (1.12–1.16) 1.06 (1.04–1.07) 1.06 (1.04–1.08)
Drug–drug interactions 2.02 (1.95–2.10) 1.62 (1.55–1.70) 1.60 (1.54–1.66)
Contraindicated drugs in chronic kidney disease 1.74 (1.72–1.76) 1.06 (1.05–1.08) 1.08 (1.06–1.09)
Contraindicated drugs in liver disease 1.59 (1.56–1.62) 1.59 (1.56–1.63) 1.54 (1.50–1.57)
Potentially inappropriate medication in older
people 1.76 (1.74–1.78) 1.31 (1.29–1.32) 1.30 (1.29–1.32)
HR: hazard ratio. * Adjusted for age, sex, socioeconomic status (MEDEA index), and level of multimorbidity.
4. Discussion
Our results show that MRPs, and especially PIMs, were very prevalent in multimorbid
older people both at baseline and at study end, especially in patients with the most
comorbidities. Presenting one or more MRPs was associated with a higher risk of mortality
at five years’ follow-up.
Multimorbidity is associated with the prescription of multiple medications, boosting
the risk of exposure to unnecessary drugs and the likelihood of duplicate therapies or
interactions, among other MRPs [41]. Aging is associated with diminished renal and liver
clearance, primarily due to the reduced blood flow and hepatocyte mass as well as sclerotic
changes in the glomeruli [14]. These factors set off changes in drug metabolism and
excretion, which can make it necessary to adjust drug dosing or use alternative treatments
that are not contraindicated in these situations.
A variety of terminology is used to conceptualize different events or circumstances
related to administering medication that could actually or potentially interfere in achieving
desired health outcomes, making it extremely difficult to compare the results obtained in
different studies [42].
A singular contribution of this study is that it analyzes the prevalence and five-
year evolution of MRPs in a large cohort of multimorbid older people. To our knowledge,
no other studies have reported longitudinal data or trends associated with duplicate therapy
or contraindicated drugs in CKD or liver disease after a follow-up period. We observed
a decrease in the proportion of patients on duplicate therapy, from 11.3% at baseline to
6.2% at five years, which is more similar to the 4.8% reported in cross-sectional studies [43].
Similarly, we saw a decrease in drug–drug interactions; this result stands in contrast
with other studies that not only reported an upward trend, but also a higher overall
prevalence of this problem [44]. These differences may be because we excluded over-the-
counter medications and dietary supplements from the analysis, instead analyzing only
formally contraindicated interactions. In addition, in 2012 the Catalan Health Institute
implemented a warning system for clinical histories in PHC to prevent medication-related
errors, including interactions and duplications. This policy could have contributed to the
decrease in these MRPs over the five-year follow-up, although a specific study investigating
this relationship would be needed to confirm this hypothesis.
On the other hand, our results show an increase in the use of contraindicated drugs in
CKD, from 11.1% at baseline to 18.5% at five years. Cross-sectional studies show wide varia-
tions (13 to 80.5%) in the proportion of patients with CKD who are prescribed inappropriate
drugs in ambulatory care [45]. As in our study, metformin is among the most common
medications used inappropriately in these patients [45]. Thus, automated warnings to
support dose adjustment in electronic prescription systems may favor appropriate drug
use in patients with CKD.
We did not identify PHC studies that analyzed contraindicated drugs in liver disease
in older patients. The influence of these pathologies on pharmacokinetics and pharma-
codynamics is complex, and currently there is no quantitative method to calculate dose
J. Clin. Med. 2021, 10, 709 11 of 14
adjustments in these patients. These challenges mean that recommendations on drug use
are imprecise, and few studies have tried to quantify this type of MRP. However, we ob-
served a high prevalence of this problem, so it needs to be considered when prescribing
drugs in older people.
With regard to the number of PIMs in the elderly patient population, the literature
reports a wide range and divergent trends. Some studies reported no significant changes
over time, while others found, as we did, that this type of MRP tends to increase over
follow-up [46,47]. Notably, the proportion of patients taking PIMs was higher in our
study (ranging from 62.5 to 71.1%) than in others. Diverse factors could play a role in
these differences; for example, variations in the criteria used to identify a PIM or in the
characteristics of included patients. Regarding the criteria for defining a PIM, we used a
comprehensive review, which could have influenced the number of PIMs identified [23].
In our study, we observed that older, multimorbid patients who presented MRPs
carry a higher risk of mortality, and the magnitude of this association is highest in those
with drug–drug interactions. Mortality associated with drug-related adverse events has
mainly been analyzed in the hospital setting, where it represents 0.15% of all inpatient
deaths—double the rate as in the rest of admitted patients [48,49]. Our study corroborates
the data reported in a hospital setting from the PHC perspective, highlighting the impact
of MRPs for both patients and the health system.
This study is based on a large, high-quality database containing PHC records that
are representative of the multimorbid population in Catalonia [18]. In addition, we used
validated, clinically driven methodology to measure chronic diseases and polypharmacy,
which allows a standardized evaluation of chronic diseases in the European Union [19].
Nevertheless, our study also has some limitations. First of all, we considered only the
medications used chronically (≥3 packages dispensed per year), thus excluding medica-
tions used to treat acute pathologies from the analysis. Secondly, the SIDIAP database only
collects information on medications prescribed by PHC and hospital-based physicians that
are dispensed in community pharmacies and covered under the national health system,
with no data on drugs dispensed in hospital, over-the-counter medications, and those not
financed by the health system. These two limitations could have caused us to underesti-
mate the frequency of MRPs [50]. Finally, due to the study methodology, it was not possible
to report patients’ adherence to treatment.
People with multimorbidity usually receive care from several prescribers, including
physicians in PHC and in hospitals [51]. Polymedication is often the result of fragmentation
of the health system, together with the application of clinical practice guidelines that focus
on a single pathology rather than holistically taking into account the complexity of patients
with multimorbidity [4]. Primary care physicians and pharmacists have an important role
in reconciling different prescriptions during care transitions and in reviewing treatments in
patients with an advanced age and multimorbidity. These professionals can help to align
drug regimens with individuals’ desired outcomes, weighing the risk–benefit balance of
treatments recommended in clinical practice guidelines.
The data on MRPs obtained in this study provide information that could inform the
design of programs for preventing MRPs in healthcare institutions. Interventions aimed at
avoiding drug-related adverse events could include integrating decision-making aids into
EHRs or implementing professional training.
5. Conclusions
The high prevalence of MRPs and their possible impact on mortality in elderly patients
with multimorbidity suggest that MRPs are a widespread public health problem. Our re-
sults show the impact of MRPs when patients have more comorbidities, affecting both
patients’ health and healthcare services.
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